The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 10 Tips for Opioid Prescribing

10 Tips for Opioid Prescribing

December 1, 2014 • By Dennis J. Boyle, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Managing the risks associated with pain medications

Editor’s note: Also see “False Assumptions”.

You Might Also Like
  • Clinicians’ Use of ‘Safer’ Opioid-Prescribing Practices Spotty
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
  • Chronic Opioid Use in Rheumatoid Arthritis: Prevalence & Predictors
Explore This Issue
December 2014
Also By This Author
  • Medication Non-Adherence by Rheumatology Patients & What Rheumatologists Can Do

Case Study 1

A 34-year-old male presented to a rheumatologist for treatment and chronic pain. The patient had severe ankylosing spondylitis (AS) and end-stage hip osteoarthritis. Orthopedics was trying to avoid performing a hip replacement on him at such a young age. The rheumatologist was comfortable prescribing opioids and has treated many patients with scheduled drugs. The patient has had chronic pain for many years and has undergone multiple treatments, including physical therapy, steroid injections and many medications. On presentation, the patient was also on methocarbamol and oxycodone/acetaminophen (four times a day). His past history was positive for hypertension and alcohol abuse, although he stated he had not consumed alcohol in the past year. He worked as a laborer.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

On exam, the patient was in moderate distress with his back pain. His blood pressure was elevated at 160/100. Low back and neurologic exam were normal. He had a decreased Schobers of 8 cm. X-rays showed severe AS and osteoarthritis of the right knee. The physician instituted infliximab at 400 mg/month, oxycodone at 10 mg (BID) for pain control and clonazepam for muscle spasm. On a follow-up visit two weeks later, the oxycodone was increased to 30 (BID).

Two days after the follow-up visit, the patient picked up the medicine at a local pharmacy. The next morning, the patient was found unarousable by his roommate and declared dead on scene by paramedics. The cause of death was polysubstance drug overdose with evidence of opioids, benzodiazepines and alcohol on the toxicology screen. A lawsuit was filed against the physician.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Case Study 2

A rheumatologist had been seeing a 65-year-old female patient for years. The patient had severe rheumatoid arthritis and had taken many prednisone courses over the years. She developed an osteoporotic thoracic spine fracture and was eventually prescribed hydrocodone/APAP 5/325, 240 pills a month.

Because of the increased publicity surrounding the opioid epidemic, the physician worried that the patient was getting too much medication. This was only one of a handful of patients in his practice on opioids. As time went on, the patient became increasingly belligerent with the physician’s staff, and he decided to terminate her from his practice. The physician wrote a dismissal letter to the patient. There were several loud and angry phone calls during the next month. Three months later, the physician received a complaint letter from the state medical board. The physician called the risk manager of his medical group and asked, “Did I do anything wrong here?”

Case Analysis

The first case revolves around the issue of responsible prescribing. Was there an adequate assessment of the risk factors for accidental overdose in this patient, and was the therapy appropriate for the patient’s diagnosis? Was there thorough documentation around the risks and benefits of opioids, and were there attempts to wean or use alternative treatments? Were there discussions with the patient about the issues of polypharmacy and concurrent use of alcohol? Was there an opioid agreement and consent in place? If the answers to these questions were documented in a manner that shows reasonable care, then this will be a very defensible case.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 5 | Single Page

Filed Under: Analgesics, Conditions, Drug Updates, Spondyloarthritis Tagged With: Ankylosing Spondylitis, Boyle, Chronic pain, drug, infliximab, opioid, Pain, patient care, prednisone, prescribe, rheumatologistIssue: December 2014

You Might Also Like:
  • Clinicians’ Use of ‘Safer’ Opioid-Prescribing Practices Spotty
  • FDA Says It Requires Boxed Warning on Some Opioid-Based Painkillers
  • Chronic Opioid Use in Rheumatoid Arthritis: Prevalence & Predictors
  • FDA Panel Backs Teva’s Abuse-Resistant Opioid Painkiller

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)